Overview

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to further assess the potency of PF-00868554, an HCV polymerase inhibitor, in subjects chronically infected with HCV by evaluating the antiviral activity of PF-00868554 in combination with current standard of care therapy, pegylated interferon-alpha2a (PEGASYS) and ribavirin (COPEGUS).

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Peginterferon alfa-2a